Chugai Pharmaceutical at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
Chugai Pharmaceutical takes part in 2 sessions at Antibody Engineering 2026 in San Diego. Its program centers on antibody designs that control when a drug becomes active and how long it lasts. One keeps the immune signal IL-12 masked until a protease releases it, and another is a longer-lasting antibody against an inactive form of TGF-beta1 for fibrotic diseases.
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
Chugai Pharmaceutical Tokyo, Japan | |
Japanese pharmaceutical company and Roche Group member known for antibody engineering technologies such as recycling and bispecific antibodies. | Talk Mon Dec 14 3:30pm–4:00pm Protease-Activated IL-12 Masking via Engineered VH Dissociation and IL-12 Intrinsic activity Enables Tunable Cytokine Activation Caging a powerful immune-signaling protein so it only switches on where tumor enzymes cut the cage open. Talk Tue Dec 15 4:45pm–5:15pm Long Acting Anti-latent TGF-β1 Recycling Antibody for Fibrotic Diseases An antibody that is recycled back out of cells, letting it block a scarring-driving growth factor for far longer. Protein engineering |
Instantly find 20 buyers from Chugai Pharmaceutical
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Informa Connect, The Antibody Society or Antibody Engineering & Therapeutics. Submit a correction